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Abstract 
Background: To examine the effectiveness of influenza vaccination against hospitalisation 
for acute cardiovascular and respiratory conditions and all-cause mortality in people with 
Type 2 diabetes, while adjusting for residual confounding.  
 
Methods: In this retrospective cohort study we used primary and secondary care data from 
the Clinical Practice Research Database, over 7 years between 2003-2004 and 2009-2010. 
124,503 adults with Type 2 diabetes were enrolled. Outcome measures included 
hospitalisation for acute myocardial infarction (AMI), stroke, heart failure and 
pneumonia/influenza and mortality. We fitted Poisson regression models for influenza and 
off-season periods to estimate Incidence Rate Ratios (IRR) for vaccinated and unvaccinated 
cohorts. Estimates for the summer, when influenza activity is low, were used to adjust for 
residual confounding. 
 
Results: Study participants contributed to 623,591 person-years of observation during the 
seven cohort years. Vaccine recipients were older and had more co-morbid conditions 
compared with non-recipients. After adjustment for covariates and residual confounding, 
vaccination was associated with significantly lower hospitalisation rates for stroke (IRR 0.70 
95% CI (0.53-0.91)), heart failure (IRR 0.78 95% CI (0.65-0.92)) and pneumonia or 
influenza (IRR 0.85 95% CI (0.74-0.99)) and all-cause mortality (IRR 0.76 95% CI (0.65-
0.83)), and a non-significant change for AMI (IRR 0.81 95% CI (0.62-1.04) during the 
influenza seasons.  
Interpretation: This study demonstrated for the first time that influenza vaccination was 
associated with reductions in hospitalisation rates for specific cardiovascular events in people 
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with Type 2 diabetes. Efforts should be focused on improvements in vaccine uptake in this 
important target group as part of comprehensive secondary prevention. 
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Introduction 
The health burden caused by seasonal influenza in the general population is substantial and 
explains much of the excess winter mortality.1-3 Evidence shows that influenza infection may 
accelerate acute thrombotic vascular events particularly in patients with ischaemic heart 
disease and cerebrovascular disease.4 For decades, vaccination has been the principle strategy 
to control influenza and its severe complications in the elderly and chronically ill, who 
account for majority of influenza-attributable deaths.1 Current influenza vaccination 
programmes in developed countries were largely implemented based on studies conducted on 
healthy adults in the 1960s which suggested 70% to 90% vaccine efficacy.5 In European 
countries, vaccination is generally restricted groups to the elderly and those with chronic 
conditions in all adult age groups,	and people in close contact with them to reduce 
transmission.6 In North America, annual influenza vaccination is universally recommended 
for all individuals aged 6 months and older.7, 8   
 
There has been an on-going controversy about the magnitude of influenza vaccine protection 
in clinical risk groups and the elderly despite being target populations within many national 
immunisation schedules.9 This controversy has been fed by a number of concerns. First, more 
recent and methodologically sounder studies have reported considerably lower vaccine 
efficacy in healthy people than earlier studies.9 Secondly, evidence from placebo-controlled 
randomised clinical trials demonstrate the effectiveness of influenza vaccine against infection 
in younger and healthy elderly people, but there is no compelling clinical trial evidence to 
indicate similar benefits in elderly chronically ill persons.10 In people with diabetes, an 
especially high-risk group for influenza-related complications, concerns were raised about 
impaired immune response to influenza vaccine.11 Given that national guidelines now 
strongly recommend influenza vaccination for the elderly and the chronically ill in many 
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countries, it is anticipated that a placebo-controlled clinical trials conducted among patients 
with high cardiovascular risk may not receive ethical approval.9 A few small clinical trials 
have tested whether influenza vaccine might reduce cardiovascular risk in patients with pre-
existing cardiovascular disease.12 However, to date none of these have been adequately 
powered to assess impacts on mortality and specific cardiovascular outcomes.12 Thirdly, 
methodological studies highlight potential flaws in observational studies, including 
inadequate adjustment for systematic differences between vaccine recipients and non-
recipients (referred to as ‘residual confounding’).9, 13 
 
In people with diabetes, studies assessing influenza vaccine effectiveness are scarce and have 
shown inconclusive results.11 None of the previous studies adjusted for residual confounding 
and most of them reported composite end-points such as hospitalisation for any cause. 
Furthermore, we are not aware of any studies assessing the potential benefits of influenza 
vaccination against individual cardiovascular events in people with Type 2 diabetes.14  
 
The primary aim of this study is to assess the effectiveness of seasonal influenza vaccine 
against hospital admissions for acute myocardial infarction (AMI), stroke and heart failure in 
patients with Type 2 diabetes, while assessing and making further adjustments for residual 
confounding using estimates obtained for the summer, when influenza activity is minimal. 
We also assessed the association between influenza vaccine and hospital admission for 
pneumonia or influenza and all-cause mortality.  
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Methods 
The Clinical Practice Research Datalink (CPRD) was used for this study. CPRD is one of the 
world’s largest computerised medical databases that holds prospective primary care 
records.15, 16 Anonymised primary care data for English practices in the CPRD are now 
available with a linkage to non-primary-care records including Hospital Episode Statistics 
(HES) data and Office for National Statistics mortality files.16 The number of practices 
participating in the data linkage is 300, representing 65% of participating practices and 5% of 
the general population in England.16 	
 
Study population 
We obtained an extract of the records of adults with Type 2 diabetes registered with the 300 
family practices participating in the data linkage between 2003-2004 and 2009-2010. Patients 
with Type 2 diabetes were identified using both diagnostic (C10) and management (66A) 
Read codes for Type 2 diabetes.17 Participants for the first cohort year from 1 September 
2003 to 31 August 2004 included patients with diabetes who were ≥18 years of age on 1 
September 2003 and had been continuously registered with participating practices during the 
preceding 12 months and throughout the cohort year. For each following study year, patients 
who newly met the eligibility criteria on 1 September were enrolled. 
 
Study periods 
Each cohort year was categorised into four time periods: pre-influenza, influenza season, 
post-influenza and summer. Date of the onset and end of influenza season was obtained for 
each year from national surveillance data on weekly GP consultation rates for influenza-like 
illness (ILI).18 According to this surveillance system, influenza season starts when weekly GP 
ILI activity exceeds the threshold of 30 per 100,000 population and ends when activity goes 
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below this threshold.19 We further defined influenza season as the time period from the date 
of onset to 4 weeks after the end of influenza season to capture delayed complications. 
 
Pre-influenza season was defined as the time period from 1 September to the date of onset of 
the influenza season. Post-influenza season was defined as the period after the influenza 
season to 30 April. Summer period was defined as 1 May to 31 August for each cohort year. 
Pre-influenza, influenza, post-influenza and summer periods were combined across all study 
years between 2003-2004 and 2009-2010. 
 
Study Variables 
The study outcomes included hospital admissions for AMI, stroke, pneumonia or influenza 
and heart failure and all-cause mortality. Hospital admissions were identified from HES as 
the principal diagnosis on admission using the 10th revision of International Classification of 
Diseases (ICD-10) codes as follows: AMI: I21–I22; stroke: I60–I64; influenza/pneumonia: 
J09–J18; heart failure: I50. During each cohort year, patients were followed from 1 
September until the occurrence of study outcomes or end of cohort year (31 August).  
 
Baseline data obtained for each cohort year included age, sex, smoking status (classified as 
current, ex-smoker, non-smoker or missing), body mass index (BMI), laboratory tests 
(cholesterol and HbA1c), systolic and diastolic blood pressure readings (SBP and DBP) and  
number of hospital admissions during the preceding 12 months. Baseline co-morbid 
conditions were defined using diagnostic Read codes included history of myocardial 
infarction, stroke, heart failure, asthma, chronic obstructive pulmonary disease, chronic 
kidney disease, cancer and atrial fibrillation. Medications prescribed were identified from 
prescription records: insulin, oral anti-hyperglycaemic, anti-hypertensive, lipid lowering, 
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anticoagulant and antiplatelet drugs and immunosuppressants. We assigned a deprivation 
score to individual patients, using the Index of Multiple Deprivation 2004 based on their 
practice postcode.20 All co-variates were re-defined at the beginning of each cohort year.  
 
Vaccination status 
Influenza vaccination status was ascertained from primary care records for each year. In 
2009-10, there was an outbreak of a pandemic influenza A(H1N1)pdm09 virus.18 Due to 
some unspecific codes that do not allow to discriminate between seasonal and pandemic 
influenza vaccination, we included all influenza vaccination codes for 2009 and 2010. All 
study participants were classified as ‘unvaccinated’ from 1 September until they received 
influenza vaccine for the subject year. Patients were classified as ‘effectively vaccinated’ 14 
days after the date of vaccination to allow for the attainment of protective antibody titres.21 
We also obtained information on history of pneumococcal polysaccharide vaccination and 
influenza vaccination during the previous year and.  
 
Statistical analysis 
Baseline characteristics of vaccinated and unvaccinated study participants were compared 
using the Chi-square test for categorical variables, Student’s t test for normally distributed 
variables, and Mann-Whitney test for skewed continuous variables, as appropriate.  
 
To estimate incidence rate ratio (IRR) with 95% confidence interval (CI) for vaccinated to 
unvaccinated cohorts, we fitted random effects Poisson regression models for each outcome. 
We performed three sets of models for each study outcome and each study period separately: 
unadjusted (vaccination status as the only predictor), models adjusted for study co-variates 
and models for the influenza period additionally adjusted for residual confounding.  
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Co-variates in the adjusted models (second set of models) included age, sex, IMD quintile, 
duration of diabetes, number of comorbid conditions, smoking status, medications (lipid-
lowering drugs, anticoagulants or antiplatelet drugs, anti-hypertensive drugs, insulin, oral 
anti-hyperglycaemic drugs and immunosuppressive drugs), SBP, DBP, BMI, serum HbA1c, 
serum cholesterol, number of hospital admissions and influenza vaccination during the 
previous year, history of pneumococcal vaccination and cohort year.   
 
Vaccine status was considered a time-varying exposure and each patient’s follow-up time 
was classified into vaccinated and unvaccinated person-time periods. Follow-up time was 
included in the models as an offset term.  Study participants could contribute to more than 
one cohort year in this study. To account for potential within-person dependency, we entered 
patients as random effects into the models.  
 
We performed an additional analysis to obtain unadjusted and adjusted IRRs and 95% 
confidence intervals excluding cohort year 2008-2009, when an outbreak of the 
A(H1N1)pdm09 pandemic strain occurred to test whether the exclusion of this year impacted 
on the results. 
 
Adjustment for residual confounding 
Given that influenza activity is minimal during the summer, vaccination should not provide 
benefits during the off-season.22, 23 Therefore, vaccinated and unvaccinated patients should 
have similar risks of outcomes during the summer period after adjustment for measured 
confounders with an expected incidence rate ratio (IRR) of 1.0 for the summer period. Effect 
estimates for the summer period were used to adjust for residual confounding occurring 
during the influenza period using the following formula.23, 24  
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IRRadjusted= exp(βinfluenza season – βsummer period) 
 
where β is the regression coefficients obtained from Poisson regression models. To calculate 
95% CIs for the effect estimates, we resampled 500 times from the distribution of the 
observed estimates for the influenza and summer periods. After having taken the difference 
of each of the 500 sampled estimates, the 2.5th and 97.5th percentile of the distribution was 
taken to obtain 95% CI for the adjusted IRRs.23, 24  
 
In all analyses, a two sided P≤0.05 was considered statistically significant. We performed 
statistical analyses using Stata version 11.0. 
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Results 
The study included 124,503 patients with Type 2 diabetes who contributed to 623,591 
person-years of observation during the 7 study years. During the study period, the 
predominant circulating influenza strains were A(H3N2) in 2003-2004, 2004-2005, 2006-
2007 and 2008-2009, B in 2005-2006 and A(H1N1) in 2007-2008 and 2009-2010 (Table 1).18 
The antigenic match between the circulating and vaccine strains was good for all study years 
except for 2003-2004 due to antigenic drift and 2009-2010 due to the occurrence of a new 
variant as a result of antigenic shift.18 Overall seasonal influenza vaccination uptake in the 
cohort ranged from 63.1% in 2008-2009 to 69.0% in 2006-2007. Across all study years, there 
were 5,142 hospital admissions for AMI, 4,515 for stroke, 14,154 for pneumonia or influenza 
and 12,915 for heart failure and 21,070 deaths were recorded. 
 
Table 2 shows the baseline characteristics of vaccine recipients and non-recipients for the 
2003-2004 and 2009-2010 cohorts. Vaccine recipients were older and generally more ill, 
having more co-existing conditions and larger number of medications prescribed but had 
lower levels of HbA1c and cholesterol compared with non-recipients.  
 
In unadjusted analyses, there was an inconsistent association between vaccination and 
outcomes during the flu season. Vaccine recipients compared with non-recipients had 
significantly higher rates of hospitalisation for AMI and heart failure, lower rates for death 
and rates did not significantly differ for stroke and pneumonia (Table 3). Vaccination was 
associated with higher event rates during the summer for all outcomes.   
 
In the models adjusted  for study covariates, IRRs attenuated for all study outcomes 
compared with the unadjusted IRRs. Influenza vaccination was associated with significant 
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reductions in all study end-points during the influenza season (Table 3). Vaccine recipients 
had 22% lower rates of AMI (IRR (95% CI) 0.78 (0.65-0.93), P<0.01), 18% lower rates of 
stroke (0.82 (0.66-1.00)), 17% reduction in heart failure rates (0.83 (0.74-0.93), P<0.001) and 
25% lower rates for pneumonia/ influenza (0.75 (0.68-0.82), P<0.001). Furthermore, 
vaccination reduced mortality rates by 50% during influenza season (IRR 95% CI 0.50 (0.45-
0.54), P<0.001). Vaccination was also associated with significantly lower event rates during 
the pre- and post-influenza seasons for all outcomes except for AMI and 
pneumonia/influenza for the pre-influenza period (Table 3). However, estimates for the 
summer period showed differences between vaccinated and unvaccinated patients in these 
models, indicating insufficient adjustment for underlying differences between these groups. 
 
After adjustment for residual confounding, vaccination was associated with 19% reduction in 
hospitalisation rate for AMI (IRR (95% CI) 0.81 (0.62-1.04)), 30% reduction in stroke (0.70 
(0.53-0.91)), 22% reduction in heart failure (0.78 (0.65-0.92)), and 15% for 
pneumonia/influenza (0.85 (0.74-0.99)) during influenza season in people who received 
vaccination compared with unvaccinated people with diabetes (Figure 1). Vaccinated patients 
had 24% lower death rates compared with non-recipients (IRR (95% CI) 0.76 (0.65-0.83)).  
 
Excluding cohort year 2008-2009 from the analysis when the pandemic A(H1N1)pdm09 was 
circulating did not qualitatively change the unadjusted and adjusted IRRs obtained for the flu 
and summer periods (Table 4). 
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Interpretation 
In this large population-based study, influenza vaccination of people with Type 2 diabetes 
was associated with reductions in hospitalisation rates for acute cardiovascular and 
respiratory diseases and in all-cause mortality across seven influenza seasons. Additional 
adjustment for residual confounding did not qualitatively alter the results of the conventional 
analyses but attenuated the associations for AMI, pneumonia/influenza and mortality and 
strengthened for stroke and heart failure. Vaccine recipients had 30% lower hospitalisation 
rates for stroke, 22% for heart failure and 15% for pneumonia/influenza and had 24% lower 
death rates compared with unvaccinated individuals. Influenza vaccination was associated 
with 19% lower rates of hospitalisation for AMI but this association was not statistically 
significant.  
 
Current policy in most developed countries strongly emphasizes the annual vaccination of 
elderly people and patients with chronic conditions including diabetes. However, there is no 
conclusive clinical trial evidence to support the benefits of influenza vaccination in these 
groups.25 In people with diabetes, epidemiological studies quantifying influenza vaccine 
protection against severe outcomes are scarce and largely inconclusive.11 A recent meta-
analysis found that in patients with diabetes aged 18-64 years, influenza vaccine prevented 
58% of all-cause hospitalisations and 43% of hospitalisations for influenza or pneumonia but 
not mortality.11 In patients over 65 years, the meta-analysis reported a pooled vaccine 
effectiveness of 38% for all-cause mortality and 23% for all-cause hospitalisation. However, 
conclusions were limited by the small number of studies identified, lack of experimental 
studies, low quality of evidence and strong residual confounding in most studies. The authors 
did not identify any studies assessing influenza vaccine effectiveness against cardiovascular 
events.  
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To better account for the systematic differences between vaccinated and unvaccinated 
patients, we have made additional adjustments for residual confounding using the summer 
period when minimal vaccine benefit is expected.13, 23, 24  Some authors have suggested using 
the pre-influenza season as a control time period. Many previous studies assessing influenza 
vaccine effectiveness among elderly people described reduced mortality associated with 
vaccination during the entire year. Often the association was the largest before influenza was 
circulating. Jackson et al. argued that frail US seniors did not tend to receive influenza 
vaccine and die unvaccinated during the follow-up time.13 They conclude that due to this 
‘frailty bias’, pre-influenza periods are the most suitable for identifying residual confounding 
because the differences in risk between vaccinated and unvaccinated groups gradually decline 
over time. However, the pattern of vaccine uptake may largely differ in countries with 
different immunisation strategies. In North America, influenza vaccine is universally 
recommended for all over the age of six months and high-risk seniors in the US were found 
less likely to receive flu vaccine. In England, although the national policy is to offer free 
influenza vaccine to all people with chronic conditions, the uptake is increasing with 
advancing age and presence of co-morbid conditions.26  
 
Many previous studies examined influenza vaccine effectiveness by analysing one single or a 
few seasons.27, 28 There are large variations across years in influenza activity, pathogenicity of 
circulating strains and degree of vaccine-virus antigenic match. In 2003-2004, vaccine-virus 
antigenic match was low. An incompletely matched vaccine might provide protection against 
serologically-confirmed influenza, but to a lesser extent than well-matched vaccines.21, 29 Due 
to these variations, evaluating vaccine effectiveness in individual seasons may yield widely 
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ranging results on vaccine benefits. Our study provides valuable information on the long-term 
average benefits of influenza vaccine in people with Type 2 diabetes.  
 
In 2009, traditional influenza activity was low but there was an outbreak of a pandemic 
influenza A(H1N1)pdm09 virus.18 Similarly to previous pandemics, this strain caused mild 
illness in most infected individuals and severe disease and mortality mostly affected children 
and young people.30 Excluding 2008-2009 from the analyses reduced statistical power due to 
the reduction in the number of events but did not change the associations found between 
vaccine and clinical outcomes. 
 
Strengths and limitations 
The strengths of this study include the use of a large population-based cohort of patients with 
Type 2 diabetes, long follow-up time the availability of key laboratory, clinical parameters, 
and medications as well as the exact date of vaccination. This study assessed for the first time 
vaccine protection against individual cardiovascular end-points instead of composite 
outcomes in people with diabetes. Furthermore, we aimed to improve on previous studies by 
assessing and making further adjustments for residual confounding. 
 
Limitations of this study include that we could not evaluate misclassification of outcomes or 
co-variates due to undiagnosed cases of outcomes or co-morbidity and unrecorded medical 
information. However, the validity of CPRD has been continuously monitored and evaluated 
as high for completeness and accuracy and the database has been extensively used for health 
research.15 Furthermore, the study included cohort years during and after the introduction of 
the Quality and Outcomes Framework when ascertainment and recording of diabetes, co-
morbidities and vaccination status are likely to be more accurate due to the financial incentive 
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provided for general practitioners to record all cases.31 Uptake of influenza vaccine identified 
in this study is broadly consistent with published national data.26 Despite efforts to reduce the 
effect of  selection bias between vaccine recipients and non-recipients, adjustments 
undertaken using the summer estimates are unlikely to eliminate residual confounding in our 
observational study.  
 
Concerns about the benefits of influenza vaccination in the elderly and chronically ill largely 
impacts on the acceptance and uptake of influenza vaccination in many countries including 
those with comprehensive immunisation programmes.25 This study has demonstrated that 
people with Type 2 diabetes may largely benefit from current vaccines including protection 
against hospital admission against some major cardiovascular outcomes. These findings 
underline the importance of influenza vaccination as part of comprehensive secondary 
prevention in this high-risk population.  
Declaration of interests: None. 
 
 
Data sharing statement: Data are available from the CPRD for additional analyses if 
necessary. 
 
Acknowledgements: 
EV designed the study, analysed the data and wrote the first draft of the paper. CM designed 
the study and co-wrote the manuscript. UP and VC analysed the data and wrote the paper. 
AM, MH and JV contributed to the design of the study and revised the paper critically for 
important intellectual content.  The Department of Primary Care & Public Health at Imperial 
College is grateful for support from the NIHR North West London CLAHRC Scheme, the 
17	
	
NIHR Biomedical Research Centre scheme, and the Imperial Centre for Patient Safety and 
Service Quality. CM is funded by an NIHR Research Professorship. 
 
 
18	
	
References 
1. Tillett HE, Smith JW, Clifford RE. Excess morbidity and mortality associated with 
influenza in england and wales. Lancet. 1980;1:793-795 
2. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda 
K. Mortality associated with influenza and respiratory syncytial virus in the united 
states. JAMA : the journal of the American Medical Association. 2003;289:179-186 
3. Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH, Schonberger LB. 
The impact of influenza epidemics on mortality: Introducing a severity index. 
American journal of public health. 1997;87:1944-1950 
4. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial 
infarction or death from cardiovascular disease: A systematic review. The Lancet 
infectious diseases. 2009;9:601-610 
5. Davenport FM. Control of influenza. The Medical journal of Australia. 
1973:Suppl:33-38 
6. Mereckiene J, Cotter S, Nicoll A, Lopalco P, Noori T, Weber J, D'Ancona F, Levy-
Bruhl D, Dematte L, Giambi C, Valentiner-Branth P, Stankiewicz I, Appelgren E, D 
OF. Seasonal influenza immunisation in europe. Overview of recommendations and 
vaccination coverage for three seasons: Pre-pandemic (2008/09), pandemic (2009/10) 
and post-pandemic (2010/11). Euro surveillance : bulletin Europeen sur les maladies 
transmissibles = European communicable disease bulletin. 2014;19:20780 
7. Public health agency of canada: National advisory committee on immunization (naci): 
Statement on seasonal influenza vaccine for 2014-2015. Available at: 
Http://www.Phac-aspc.Gc.Ca/naci-ccni/flu-grippe-eng.Php#v (last accessed: 17 
december 2015).  
8. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention 
and control of influenza with vaccines: Recommendations of the advisory committee 
19	
	
on immunization practices, united states, 2015-16 influenza season. American journal 
of transplantation : official journal of the American Society of Transplantation and 
the American Society of Transplant Surgeons. 2015;15:2767-2775 
9. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of 
influenza vaccination in elderly people: An ongoing controversy. The Lancet 
infectious diseases. 2007;7:658-666 
10. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of 
influenza vaccines: A systematic review and meta-analysis. The Lancet infectious 
diseases. 2012;12:36-44 
11. Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal 
influenza in patients with diabetes: Systematic review and meta-analysis. BMC 
medicine. 2015;13:53 
12. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, 
Ciszewski A, Vakili H, Hoffman EB, Farkouh ME, Cannon CP. Association between 
influenza vaccination and cardiovascular outcomes in high-risk patients: A meta-
analysis. JAMA : the journal of the American Medical Association. 2013;310:1711-
1720 
13. Jackson ML, Yu O, Nelson JC, Naleway A, Belongia EA, Baxter R, Narwaney K, 
Jacobsen SJ, Shay DK, Jackson LA. Further evidence for bias in observational studies 
of influenza vaccine effectiveness: The 2009 influenza a(h1n1) pandemic. American 
journal of epidemiology. 2013;178:1327-1336 
14. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, 
Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with 
acute coronary syndrome. Eur Heart J. 2011;32:1730-1735 
20	
	
15. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of 
diagnoses in the general practice research database: A systematic review. British 
journal of clinical pharmacology. 2010;69:4-14 
16. Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the 
general practice research database as an example of a uk primary care data resource. 
Ther Adv Drug Saf. 2012;3:88-99 
17. Gray J, Orr D, Majeed A. Use of read codes in diabetes management in a south 
london primary care group: Implications for establishing disease registers. Bmj. 
2003;326:1130 
18. Health protection agency: National influenza weekly reports archive. Available at: 
Http://www.Hpa.Org.Uk/topics/infectiousdiseases/infectionsaz/seasonalinfluenza/epi
demiologicaldata/05influsweeklyinfluenzareportsarchive/ (last accessed: 10 march 
2015).  
19. Goddard NL, Kyncl J, Watson JM. Appropriateness of thresholds currently used to 
describe influenza activity in england. Communicable disease and public health / 
PHLS. 2003;6:238-245 
20. Department for communities and local government: Index for multiple deprivation 
2004. Available at: Http://data.Gov.Uk/dataset/imd_2004 (last accessed: 5 september 
2015).  
21. Dean AS, Moffatt CR, Rosewell A, Dwyer DE, Lindley RI, Booy R, MacIntyre CR. 
Incompletely matched influenza vaccine still provides protection in frail elderly. 
Vaccine. 2010;28:864-867 
22. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza 
vaccine in the community-dwelling elderly. The New England journal of medicine. 
2007;357:1373-1381 
21	
	
23. Groenwold RH, Hoes AW, Hak E. Impact of influenza vaccination on mortality risk 
among the elderly. The European respiratory journal. 2009;34:56-62 
24. Weiner MG, Xie D, Tannen RL. Replication of the scandinavian simvastatin survival 
study using a primary care medical record database prompted exploration of a new 
method to address unmeasured confounding. Pharmacoepidemiology and drug safety. 
2008;17:661-670 
25. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in 
healthy adults. The Cochrane database of systematic reviews. 2004:CD001269 
26. Health protection agency: National influenza annual reports available at: 
Http://webarchive.Nationalarchives.Gov.Uk/20140714084352/http://www.Hpa.Org.U
k/topics/infectiousdiseases/infectionsaz/seasonalinfluenza/epidemiologicaldata/07infl
usinfluenzaannualreports/  (last accessed: 17 december 2015).  
27. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. 
Vaccines for preventing influenza in the elderly. The Cochrane database of systematic 
reviews. 2010:CD004876 
28. Yao X, Hamilton RG, Weng NP, Xue QL, Bream JH, Li H, Tian J, Yeh SH, Resnick 
B, Xu X, Walston J, Fried LP, Leng SX. Frailty is associated with impairment of 
vaccine-induced antibody response and increase in post-vaccination influenza 
infection in community-dwelling older adults. Vaccine. 2011;29:5015-5021 
29. Jefferson TO, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V. Vaccines for 
preventing influenza in healthy adults. The Cochrane database of systematic reviews. 
2007:CD001269 
30. Green HK, Andrews N, Fleming D, Zambon M, Pebody R. Mortality attributable to 
influenza in england and wales prior to, during and after the 2009 pandemic. PloS 
one. 2013;8:e79360 
22	
	
31. Health & social care information centre: The quality and outcomes framework. 
Available at: Http://www.Hscic.Gov.Uk/qof (last accessed: 10 december 2015).  
 
23	
	
Table 1. Characteristics of Study Cohort Years from 2003-2004 to 2009-2010 
 Study Cohort Year 
2003-2004 2004-2005 2005-2006 2006-2007 2007-2008 2008-2009 2009-2010 
Influenza season, week 
number (date)  
Onset 
End 
No of patients entering the 
cohort 
Total person-years 
No of hospital admissions for 
AMI 
Stroke 
Pneumonia/Influenza 
Heart Failure 
No of deaths for all-cause 
Vaccination coverage, % 
Vaccine coverage among 
vaccine recipients by the start 
of the influenza season, % 
Predominant virus circulating  
 
 
Vaccine-virus antigenic match 
 
 
46 (13 November) 
49 (5 December) 
67,067 
 
66,157.3 
 
639 
518 
1,233 
1,312 
1,899 
66.54 
86.1 
 
 
A(H3N2)  
Fujian/411/2002 
 
Low 
 
 
1 (6 January) 
6 (11 February) 
76,215 
 
74,779.1 
 
676 
561 
1,560 
1,503 
2,507 
68.4 
97.7 
 
 
A(H3N2) 
Wellington/01/ 
2004  
Good 
 
 
5 (27 January) 
8 (23 February) 
84,780 
 
83,111.6 
 
713 
635 
1,761 
1,713 
2,903 
69.0 
98.9 
 
 
B 
Hong Kong/ 
330/2001  
Good 
 
 
5 (26 January) 
9 (1 March) 
92,732 
 
90,951.3 
 
725 
654 
2,021 
1,783 
3,124 
65.7 
98.5 
 
 
A(H3N2)  
Wisconsin/67/05 
 
Good 
 
 
1 (31 December) 
2 (13 January) 
100,187 
 
98,488.5 
 
798 
702 
2,267 
2,045 
3,390 
63.9 
97.3 
 
 
A(H1N1) 
Solomon Island 
/3/2006  
Good 
 
 
50 (5 December) 
3 (15 January) 
107,323 
 
105,218.2 
 
816 
749 
2,626 
2,224 
3,611 
63.1 
94.0 
 
 
A(H3N2) 
Brisbane/10/2007 
 
Good 
 
 
42 (9 October) 
49 (3 December) 
107,013 
 
104,884.6 
 
775 
696 
2,686 
2,335 
3,636 
65.0 
37.8 
 
 
A(H1N1) 
California/07/2009 
 
No match 
Note: AMI: Acute Myocardial Infarction
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Table 2.Characteristics of people with diabetes at the baseline of the 2003/04 and 2009/10 cohort years who received and who did not 
receive influenza vaccination.	
 2003-2004 2009-2010 
 Influenza Vaccine  Influenza Vaccine  
Yes No P Yes No P 
No. of subjects (%) 
Age, yr, mean ± SD 
<65 years, N (%) 
65-70 years 
71-80 years 
81 years or above 
Male sex, N (%) 
Smoking, N (%) 
Current 
Non 
Ex 
Missing data 
BMI, mean ± SD, kg/m2 
Cholesterol, mean ± SD, mmol/l 
SBP, mean ± SD, mm Hg 
DBP, mean ± SD, mm Hg 
HbA1c, mean ± SD, %  
No. of co-morbid conditions, 
median (IQR) 
Recorded clinical history, N (%) 
Heart failure 
Stroke 
44,604 (66.5) 
66.2 ± 13.3 
17,309 (38.8) 
8,676 (19.5) 
14,006 (31.4) 
4,613 (10.3) 
24,038 (53.9) 
 
5,454 (12.2) 
20,774 (46.6) 
16,915 (37.9) 
1,461 (3.3) 
29.5 ± 6.0 
4.7 ± 1.0 
141.0 ± 15.9 
77.9 ± 8.5 
7.5 ± 1.41  
(0 - 2) 
 
 
4,503 (10.1) 
1,857 (4.2) 
22,463 (33.5) 
56.2 ± 16.3 
15,517 (69.1) 
2,319 (10.3) 
3,229 (14.4) 
1,398 (6.2) 
12,179 (54.2) 
 
4,442 (19.8) 
10,074 (44.8) 
5,996 (26.7) 
1,951 (8.7) 
30.1 ± 6.5 
5.0 ± 1.1 
138.9 ± 17.9 
80.4 ± 9.8 
7.9 ± 1.80 
 (0 - 1) 
 
 
990 (4.4) 
1,504 (6.7) 
- 
<0.001† 
<0.001‡ 
 
 
 
 
<0.001‡ 
<0.001‡ 
 
 
 
<0.001† 
<0.001† 
<0.001† 
<0.001† 
<0.001† 
<0.001¥ 
 
 
<0.001‡ 
<0.001‡ 
69,594 (65.0) 
65.8 ± 13.8 
29,463 (42.3) 
11,470 (16.5) 
20,612 (29.6) 
8,049 (11.6) 
38,190 (54.9) 
 
8,455 (12.2) 
33,533 (48.2) 
27,515 (39.5) 
91 (0.1) 
30.5 ± 6.4 
4.3 ± 1.0 
135.5 ± 14.2 
75.9 ± 8.6 
7.3 ± 1.4 
1 (0 - 2) 
 
 
4,578 (6.6) 
6,525 (9.4) 
37,419 (35.0) 
58.4 ± 17.2 
22,875 (61.1) 
4,491 (12.0) 
6,581 (17.6) 
3,472 (9.3) 
18,971 (50.7) 
 
7,087 (18.9) 
17,679 (47.2) 
10,937 (29.2) 
1,716 (4.6) 
30.5 ± 6.9 
4.6 ± 1.1 
134.9 ± 16.6 
78.2 ± 9.7 
7.7 ± 1.80  
(0 - 1) 
 
 
1,616 (4.3) 
2,604 (6.9) 
- 
<0.001† 
<0.001‡ 
 
 
 
 
<0.001‡ 
<0.001‡ 
 
 
 
0.137† 
<0.001† 
<0.001† 
<0.001† 
<0.001† 
<0.001¥ 
 
 
<0.001‡ 
<0.001‡ 
Continued Table 2. 
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 2003-2004 2009-2010 
 Influenza Vaccine Influenza Vaccine 
 Yes No P Yes No P 
Myocardial Infarction 
COPD 
Asthma 
Cancer 
Atrial fibrillation 
Chronic kidney disease 
Medications, N (%) 
Oral anti-hyperglycaemic 
Insulin 
Anti-hypertensive 
ACE or ARB  
Beta-blocker 
Other 
Lipid lowering 
Anticoagulants/antiplatelet  
Immunosuppressant 
No of medications, median (IQR) 
Hospital admissions during past 12 
months, N (%) 
Pneumococcus vaccine during past 5 
years, N (%) 
Influenza vaccine during past 12 
months, N (%) 
3,731 (8.4) 
4,750 (10.6) 
5,900 (13.2) 
2,524 (5.7) 
3,280 (7.3) 
2,276 (5.1) 
 
28,007 (62.8) 
9,782 (21.9) 
 
24,476 (54.9) 
16,215 (36.4) 
27,897 (62.5) 
22,301 (50.0) 
22,315 (50.0) 
687 (1.5) 
4 (2 - 6) 
11,552 (25.8) 
 
15,995 (35.9) 
 
35,940 (80.6) 
1,313 (5.8) 
410 (1.8) 
2,377 (10.6) 
773 (3.4) 
785 (3.5) 
625 (2.8) 
 
10,438 (46.5) 
4,589 (20.4) 
 
7,779 (34.6) 
5,547 (24.7) 
8,880 (39.5) 
7,083 (31.5) 
6,458 (28.7) 
224 (1.0) 
2 (1 - 4) 
4,726 (21.0) 
 
2,638 (11.7) 
 
3,473 (15.5) 
<0.001‡ 
<0.001‡ 
<0.001‡ 
<0.001‡ 
<0.001‡ 
<0.001‡ 
 
<0.001‡ 
<0.001‡ 
 
<0.001‡ 
<0.001‡ 
<0.001‡ 
<0.001‡ 
<0.001‡ 
<0.001‡ 
<0.001§ 
<0.001‡ 
 
<0.001‡ 
 
<0.001‡ 
3028 (8.7) 
4631 (6.6) 
10,348 (14.9) 
4,844 (7.0) 
5,439 (7.8) 
19,164 (27.5) 
 
49,302 (70.8) 
14,911 (21.4) 
 
49,092 (70.5) 
28,999 (71.8) 
46,316 (66.5) 
57,228 (82.2) 
43,354 (62.3) 
1,517 (2.2) 
5 (3 - 7) 
19,531 (28.1) 
 
28,904 (41.5) 
 
60,016 (86.2) 
 
2121 (5.7) 
1203 (3.2) 
4,738 (12.7) 
1,627 (4.3) 
1,730 (4.6) 
5,811 (15.5) 
 
25,305 (67.6) 
8,555 (22.9) 
 
19,826 (53.0) 
11,402 (30.5) 
18, 350 (49.0) 
23,406 (62.5) 
16,875 (45.1) 
499 (1.3) 
4 (2 - 6) 
9,579 (25.6) 
 
7,627 (20.4) 
 
7,110 (19.0) 
<0.001‡ 
<0.001‡ 
<0.001‡ 
<0.001‡ 
<0.001‡ 
<0.001‡ 
 
<0.001‡ 
<0.001‡ 
 
<0.001‡ 
<0.001‡ 
<0.001‡ 
<0.001‡ 
<0.001‡ 
<0.001‡ 
<0.001§ 
<0.001‡ 
 
<0.001‡ 
 
<0.001‡ 
Note: BMI: Body Mass Index; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; COPD: Chronic Obstructive Pulmonary Disease; IQR: 
Interquartile Range; ACE: Angiotensin Converting Enzyme inhibitors, ARB: Angiotensin Receptor Blockers 
† Student’s t-test; ‡Chi-square test; § Mann-Whitney test 
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Table 3. Risk of hospitalisation among people with Type 2 diabetes who received influenza vaccination relative to people who did not receive 
vaccination for periods before, during and after influenza season and during the summer, across all study years between 2003-2004 and 2009-2010. 
Outcome 
 Vaccinated  Unvaccinated Unadjusted modelc Adjusted modeld 
Study Periodsa No of events PY Rateb No of events PY Rateb IRRe (95% CI) IRRe (95% CI) 
Hospital admissions for 
acute myocardial 
infarction 
 
 
Hospital admissions for 
stroke 
 
 
 
Hospital admission for 
heart failure 
 
 
 
Hospital admission for 
pneumonia/influenza 
 
 
 
All-cause mortality 
 
 
Pre-influenza  
Influenza 
Post-influenza 
Summer  
 
Pre-influenza  
Influenza 
Post-influenza 
Summer  
 
Pre-influenza  
Influenza 
Post-influenza 
Summer  
 
Pre-influenza  
Influenza 
Post-influenza 
Summer  
 
Pre-influenza  
Influenza 
Post-influenza 
Summer  
 
452 
580 
712 
1,133 
 
323 
486 
559 
1,046 
 
1,180 
1,617 
1,790 
2,770 
 
1,245 
1,908 
1,989 
2,623 
 
1,381 
2,294 
2,838 
4,732 
 
49,181.9 
64,633.9 
80,677.7 
139,014.5 
 
49,210.8 
64,688.4 
80,768.3 
139,220.9 
 
49,005.6 
64,288.5 
80,067.4 
137,484.2 
 
49,076.0 
64,331.7 
80,081.9 
137,505.4 
 
49,243.8 
64,569.0 
80,362.3 
137,644.4 
 
9.19 
8.97 
8.83 
8.15 
 
6.56 
7.51 
6.92 
7.51 
 
24.08 
25.15 
22.36 
20.15 
 
25.37 
29.66 
24.84 
19.08 
 
28.04 
35.53 
35.32 
34.38 
1,174 
329 
316 
446 
 
1,102 
310 
331 
358 
 
3,199 
813 
676 
870 
 
3,007 
1,307 
919 
1,156 
 
4,441 
1,797 
1,464 
2,123 
135,674.6 
43,597.7 
43,305.6 
72,567.9 
 
135,678.7 
43,594.4 
43,291.6 
72,555.7 
 
135,431.5 
43,412.2 
43,008.7 
71,943.3 
 
135,478.0 
43,326.2 
42,845.0 
71,571.1 
 
135,812.9 
43,029.2 
42,403.0 
70,526.3 
8.65 
7.55 
7.30 
6.15 
 
8.12 
7.11 
7.65 
4.93 
 
23.62 
18.73 
15.72 
12.09 
 
22.20 
30.17 
21.45 
16.15 
 
32.70 
41.76 
34.53 
30.10 
1.06 (0.95 - 1.18) 
1.18 (1.03 - 1.36)* 
1.20 (1.05 - 1.38)** 
1.32 (1.18 - 1.47)*** 
 
0.81 (0.71 - 0.91)*** 
1.05 (0.91 - 1.21) 
0.90 (0.78 - 1.03) 
1.53 (1.35 - 1.73)*** 
 
0.99 (0.92 - 1.06) 
1.28 (1.17 - 1.40)*** 
1.40 (1.27 - 1.53)*** 
1.65 (1.52 - 1.79)*** 
 
1.15 (1.07 - 1.23)*** 
0.96 (0.89 - 1.03) 
1.15 (1.06 - 1.25)*** 
1.18 (1.10 - 1.27)*** 
 
0.86 (0.81 - 0.91)*** 
0.85 (0.80 - 0.90)*** 
1.02 (0.96 - 1.09) 
1.14 (1.08 - 1.20)*** 
0.91 (0.81-1.03) 
0.78 (0.65 - 0.93)** 
0.87 (0.71 - 1.05) 
0.96 (0.82-  1.12) 
 
0.74 (0.65 - 0.85)*** 
0.82 (0.67 – 1.00) 
0.73 (0.59 - 0.89)** 
1.17 (1.00-1.41) 
 
0.88 (0.82 - 0.95)*** 
0.83 (0.74 - 0.93)*** 
0.84 (0.73 - 0.95)** 
1.06 (0.95 - 1.18) 
 
1.08 (1.01 - 1.17) 
0.75 (0.68 - 0.82)*** 
0.86 (0.77 - 0.97)** 
0.88 (0.80 - 0.98)* 
 
0.77 (0.72 - 0.83)*** 
0.50 (0.45 - 0.54)*** 
0.58 (0.52 - 0.65)*** 
0.66 (0.61 - 0.72)*** 
a  Pre-influenza season was defined as the time period from 1 September to the onset of the influenza season. Influenza season was defined as the time period from the onset 
to the end of the influenza season and an additional 4 weeks to capture delayed complications. Post-influenza season was defined as the period after the influenza season to 30 
April each year. Summer period was defined as 1 May to 31 August for each cohort year. 
b Rates are expressed as per 1,000 patient years  
c Models with vaccination status as the only predictor 
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d Models are adjusted for age, sex, Index of Multiple Deprivation quintile, number of comorbid conditions, duration of diabetes, body mass index, smoking status, systolic 
and diastolic blood pressure, serum cholesterol and HbA1c, lipid-lowering drugs, anticoagulants or antiplatelet drugs, anti-hypertensive drugs, insulin, oral anti-
hyperglycaemic drugs and immunosuppressive drugs, number of hospital admissions during previous year, history of Pneumococcus vaccination, influenza vaccination 
during previous year and cohort year.	 
e IRR: Incidence Rate Ratio, *** P≤0.001; ** P≤0.01; * P≤0.05 
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Table 4. Risk of hospitalisation among people with Type 2 diabetes who received influenza vaccination relative to people who did not receive 
vaccination for influenza season and summer between 2003-2004 and 2009-2010, excluding 2008-2009 when the outbreak of pandemic 
A(H1N1)pdm09 occurred. 
 
Outcome 
 Unadjusted modelb Adjusted modelc 
Study Periodsa IRRd (95% CI) IRRd (95% CI) 
 
Hospital admissions for acute 
myocardial infarction 
 
 
Hospital admissions for stroke 
 
 
 
Hospital admission for heart 
failure 
 
 
Hospital admission for 
pneumonia/influenza 
 
 
All-cause mortality 
 
 
 
Influenza 
Summer  
 
  
Influenza 
Summer  
 
  
Influenza 
Summer  
 
  
Influenza 
Summer  
 
  
Influenza 
Summer  
 
 
1.17 (1.01 - 1.36)* 
1.27 (1.13 - 1.44)*** 
 
 
1.07 (0.91 - 1.25) 
1.44 (1.26 - 1.64)*** 
 
 
1.25 (1.14 - 1.38)*** 
1.59 (1.45 - 1.74)*** 
 
 
0.97 (0.89 - 1.05) 
 1.19 (1.09 - 1.28)*** 
 
 
0.87 (0.81 - 0.93)*** 
1.14 (1.08 - 1.21)*** 
 
0.76 (0.62 - 0.93)** 
0.91 (0.77-  1.08) 
 
 
0.86 (0.69 – 1.07) 
1.13 (0.93-1.36) 
 
 
0.82 (0.72 - 0.93)** 
1.03 (0.91 - 1.16) 
 
 
0.76 (0.68 - 0.85)*** 
0.89 (0.79 - 0.99)* 
 
 
0.52 (0.47 - 0.58)*** 
0.67 (0.61 - 0.73)*** 
 
a  Influenza season was defined as the time period from the onset to the end of the influenza season and an additional 4 weeks to capture delayed complications. Summer 
period was defined as 1 May to 31 August for each cohort year (excluding 2008-2009 from the analysis) 
b Models with vaccination status as the only predictor 
c Models are adjusted for age, sex, Index of Multiple Deprivation quintile, number of comorbid conditions, duration of diabetes, body mass index, smoking status, systolic 
and diastolic blood pressure, serum cholesterol and HbA1c, lipid-lowering drugs, anticoagulants or antiplatelet drugs, anti-hypertensive drugs, insulin, oral anti-
hyperglycaemic drugs and immunosuppressive drugs, number of hospital admissions during previous year, history of Pneumococcus vaccination, influenza vaccination 
during previous year and cohort year.	 
d IRR: Incidence Rate Ratio, *** P≤0.001; ** P≤0.01; * P≤0.05 
